Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company focused on Inflammatory Bowel Disease (IBD) treatment, has announced the approval of inducement awards by its independent Compensation Committee. The awards include:
1. Stock options to purchase 400,000 shares of common stock granted to Dr. Sheldon Sloan, the new Chief Medical Officer.
2. Stock options to purchase an aggregate of 129,000 shares of common stock granted to four non-executive employees.
These equity inducement awards were approved on October 1, 2024, under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. The stock options have a 10-year term and an exercise price of $27.46, matching the closing price of Spyre's common stock on October 1, 2024. The vesting schedule includes 25% after one year and 1/48th monthly thereafter, subject to continuous service with Spyre.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), una società biotech in fase clinica focalizzata sul trattamento della Malattia Infiammatoria Intestinale (IBD), ha annunciato l'approvazione di premi di indennizzo da parte del suo Comitato di Compensazione indipendente. I premi includono:
1. Opzioni su azioni per l'acquisto di 400.000 azioni ordinarie concesse al Dr. Sheldon Sloan, il nuovo Chief Medical Officer.
2. Opzioni su azioni per l'acquisto di un totale di 129.000 azioni ordinarie concesse a quattro dipendenti non esecutivi.
Questi premi di indennizzo in equity sono stati approvati il 1 ottobre 2024, nell'ambito del Piano di Indennizzo Equity 2018 di Spyre Therapeutics, Inc. Le opzioni su azioni hanno un termine di 10 anni e un prezzo di esercizio di $27.46, corrispondente al prezzo di chiusura delle azioni ordinarie di Spyre del 1 ottobre 2024. Il programma di maturazione prevede il 25% dopo un anno e 1/48 mensile successivo, soggetto a servizio continuato con Spyre.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), una compañía biotecnológica en etapa clínica enfocada en el tratamiento de la Enfermedad Inflamatoria Intestinal (IBD), ha anunciado la aprobación de premios de inducción por parte de su Comité de Compensación independiente. Los premios incluyen:
1. Opciones sobre acciones para la compra de 400,000 acciones ordinarias otorgadas al Dr. Sheldon Sloan, el nuevo Director Médico.
2. Opciones sobre acciones para la compra de un total de 129,000 acciones ordinarias otorgadas a cuatro empleados no ejecutivos.
Estos premios de inducción en acciones fueron aprobados el 1 de octubre de 2024, bajo el Plan de Inducción de Acciones de Spyre Therapeutics, Inc. de 2018. Las opciones sobre acciones tienen un plazo de 10 años y un precio de ejercicio de $27.46, que coincide con el precio de cierre de las acciones ordinarias de Spyre el 1 de octubre de 2024. El calendario de adquisición incluye el 25% después de un año y 1/48 mensual posteriormente, sujeto a un servicio continuo con Spyre.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), 염증성 장 질환 (IBD) 치료에 주력하는 임상 단계 생명공학 회사가 독립 보상 위원회에 의해 유도 보상 승인 소식을 발표했습니다. 보상 내용은 다음과 같습니다:
1. 셸돈 슬로안 박사에게 부여된 400,000주 보통주를 구매할 수 있는 주식 옵션.
2. 네 명의 비임원 직원에게 총 129,000주 보통주를 구매할 수 있는 주식 옵션.
이 자산 유도 보상은 2024년 10월 1일 젠 가 승인 되었으며, Spyre Therapeutics, Inc. 2018 자산 유도 계획에 따라 진행됩니다. 주식 옵션은 10년의 기간을 가지며 행사 가격은 $27.46로, 2024년 10월 1일 Spyre의 보통주 종가와 일치합니다. 보상 일정은 1년 후 25% 취득, 이후 매달 1/48씩 진행되며 Spyre에 대한 지속적인 서비스에 따라 조건이 붙습니다.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), une entreprise de biotechnologie en phase clinique spécialisée dans le traitement des maladies inflammatoires de l'intestin (IBD), a annoncé l'approbation de prix d'incitation par son Comité de Rémunération indépendant. Les prix incluent :
1. Options d'achat d'actions pour acquérir 400 000 actions ordinaires accordées au Dr Sheldon Sloan, le nouveau Directeur Médical.
2. Options d'achat d'actions pour acquérir au total 129 000 actions ordinaires accordées à quatre employés non exécutifs.
Ces prix d'incitation en actions ont été approuvés le 1er octobre 2024, dans le cadre du Plan d'Incitation en Actions 2018 de Spyre Therapeutics, Inc. Les options d'achat d'actions ont une durée de 10 ans et un prix d'exercice de 27,46 $, correspondant au prix de clôture des actions ordinaires de Spyre du 1er octobre 2024. Le calendrier d'acquisition comprend 25 % après un an et 1/48 mensuel par la suite, sous réserve d'un service continu au sein de Spyre.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von entzündlichen Darmerkrankungen (IBD) spezialisiert hat, hat die Genehmigung von Anreizvergütungen durch sein unabhängiges Vergütungskomitee bekannt gegeben. Die Vergütungen umfassen:
1. Aktienoptionen zum Kauf von 400.000 Stammaktien, die Dr. Sheldon Sloan, dem neuen Chief Medical Officer, gewährt wurden.
2. Aktienoptionen zum Kauf von insgesamt 129.000 Stammaktien, die vier nicht-geschäftsführenden Angestellten gewährt wurden.
Diese Eigenkapitalanreizvergütungen wurden am 1. Oktober 2024 im Rahmen des Spyre Therapeutics, Inc. 2018 Equity Inducement Plans genehmigt. Die Aktienoptionen haben eine Laufzeit von 10 Jahren und einen Ausübungspreis von 27,46 $, der mit dem Schlusskurs der Stammaktien von Spyre am 1. Oktober 2024 übereinstimmt. Der Vesting-Zeitplan umfasst 25 % nach einem Jahr und 1/48 monatlich danach, unter der Voraussetzung einer kontinuierlichen Dienstleistung bei Spyre.
- Appointment of Dr. Sheldon Sloan as Chief Medical Officer
- Granting of stock options to attract and retain key talent
- None.
The stock options were granted with a 10-year term and an exercise price equal to
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
For Media:
Peg Rusconi
Peg.rusconi@vergescientific.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-grants-of-inducement-awards-302265133.html
SOURCE Spyre Therapeutics, Inc.
FAQ
What inducement awards did Spyre Therapeutics (SYRE) announce on October 4, 2024?
What is the exercise price of the stock options granted by Spyre Therapeutics (SYRE) on October 1, 2024?
What is the vesting schedule for the stock options granted by Spyre Therapeutics (SYRE)?
